



HEALTH TECHNOLOGY  
ASSESSMENT INTERNATIONAL


---

# Asia Policy Forum

# Overview

Attended by representatives from 10 countries + WHO/WPRO + patient rep(s):

A unique opportunity for industry and senior HTA agencies and payer representatives to discuss key HTA issues.



# Past topics and locations



**2013**  
**S. Korea**

How can available resources be used to deliver high quality HTA for health system decision makers?




**2014**  
**Philippines**

Transferability of HTA



**2015**  
**Singapore**

How can HTA meet the needs of health system and government decision makers?



**2016**  
**Malaysia**

Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement



**2017**  
**China**

Overcoming the barriers to achieving UHC in the Asian region using HTA and Real World Data

# Outputs

- **Post meeting report/communique plus key messages (PF members only)**
  - within 72 hours
- **Publications:**
  - Background paper (available on HTAi website after the meeting, PF members receive in advance)
  - International Journal of Technology Assessment in Health Care peer-reviewed article
  - Newsletter/blogs/other publications (case-by-case)
- **Conference proceedings:**
  - HTAi annual meeting, ISPOR events, national meetings and workshops



# Value

- The opportunity to **interact and network** with various stakeholders (i.e. HTA bodies, leaders of health system payer/coverage bodies and industry market access)
- The opportunity for **open discussion** of relevant and pertinent topics
- **Group discussions** and informal networking
- **Direct impact** on local HTA policies

**The opportunity for stakeholder collaboration and discussion is highly valued.**

# 2018 Asia Policy Forum


- Jakarta, Indonesia, 29 & 30 October 2018
- *"Access to high cost technologies with a focus on Managed Entry Schemes"*
- Supported by esteemed organising committee and chaired by Professor Brendon Kearney
- 13 companies (2 delegates per company)
- 12 countries plus WHO and HTAi Board members – range of stakeholders (payers, HTA agencies, patient representative)

# Survey and background paper

- Few policies on dealing with high-cost technologies exist in the region
- Survey of agencies and industry was conducted. There was broad agreement noted on:
  - Challenges in accessing high-cost technologies; uncertainty created by lack of data and budget impact/affordability
  - Experience of MES in the region is limited to date (with financial schemes most common)




# Managed Entry Schemes





# Cases by Therapeutic Area



Source: UW PBRSA Database

# Key messages

- A clear, simple definition of high-cost is not simple!
- There are common principles that are relevant across all countries in the region, however local context is critical
- Principles include:
  - Transparency
  - Affordability/budget impact
  - Severity/burden of disease
  - Value/impact of technologies
  - Time horizon and consideration of an entire care pathway
- Price negotiation is challenging; is there the possibility to learn and do together across the region?
- Disinvestment is important in considering how to fund innovative technologies

# Key messages – MES

- Access for patients is the primary driver; MES may or may not be the answer
- Simplicity, however, is key; solutions should be pragmatic, affordable and sustainable
- Drugs/devices/rare diseases should be treated separately
- Realistic expectations on patients for long-term data collection
- MES should fit-for-purpose and be the exception not the rule  
– a road map (guidelines) are needed to be clear about the intent and need for MES in the region

# Next Steps

- Post-meeting report and publications (HTAi 2019 panel session)
- Development of a consensus statement
- Dissemination with HTAi Interest Groups
- Follow up at 2019 Asia Policy Forum



# Thank You

1-780-448-4881 | [info@htai.org](mailto:info@htai.org) | [htai.org](http://htai.org)  
Follow us on Twitter, Facebook, Linked In @HTAiorg